Skincare CEO Admits Selling Unapproved Injectables for Years

Bryce Cleveland, the 42-year-old president and CEO of Arizona skincare company Scalpa Inc., has pleaded guilty to three federal charges stemming from the sale of injectable cosmetic products that were never approved by the U.S. Food and Drug Administration (FDA).

Cleveland admitted to mail fraud, introduction of an adulterated device into interstate commerce, and introduction of an unapproved new drug into interstate commerce. Federal prosecutors say that between March 2018 and December 2020 he ran a scheme to market and deliver unapproved products — including the ScalpaJECT Hyaluronic Acid, the Hyaluron Pen and a botulinum toxin product called Scalpatox — while telling customers the items were not subject to FDA regulation.

The plea includes an agreement to serve between four and eight years in prison, to pay restitution covering the full scope of the conduct, and to forfeit $800,000. Cleveland was indicted in July 2024, located in Colombia late last year and returned to the U.S., where U.S. Marshals arrested him on the outstanding warrant.

The case highlights an enforcement focus on injectable products, which bypass key defenses when delivered into the body. The FDA warned website operators on Nov. 5, 2025 about illegal marketing of unapproved botulinum toxin products, citing adverse events including symptoms of botulism.

Advertisement

FDA Enforcement Moves From Website Warnings to Prison Terms

A Warning That Became a Prosecution

The FDA's Nov. 5, 2025 warning to website owners illegally marketing unapproved botulinum toxin products was the public notice; Cleveland's guilty plea is the enforcement follow-through. The agency said it is aware of adverse events linked to such products, including botulism symptoms. Taken together, the warning and this conviction signal that the FDA and the Justice Department treat gray-market injectables as a public health problem, not a routine consumer complaint.

Why Regulators Treat Injectables Differently

Topical cosmetics sit on the skin; injectables go beneath it. The government's case notes that injectable products are delivered directly into the body, sometimes directly into the bloodstream, bypassing defenses against toxins and microorganisms. That is the medical rationale for describing unapproved fillers, pens and botulinum toxin products as especially concerning — and for stacking two types of charges, treating misbranded products as adulterated devices and unapproved formulations as new drugs.

What the Case Means for the Aesthetic Injectables Market

Verified facts end with the plea agreement; the market interpretation goes a step beyond them. Legitimate, FDA-approved neuromodulators and fillers compete with cheaper unapproved products sold online and through some clinics. Each enforcement action removes one gray-market seller and raises the risk profile for the rest, which over time favors compliant manufacturers. Consumers, however, may struggle to distinguish an approved product from an unapproved or counterfeit one — which is why the government sought restitution covering the full scope of Cleveland's conduct.

Checking an Injectable's FDA Status Before You or Your Clinic Buys

This case was built on a specific deception: telling buyers that injectable products were not subject to FDA regulation. That claim is a useful test for anyone purchasing or offering aesthetic injectables.

For consumers

  • Ask the provider for the exact product name before the procedure and check it against FDA approvals.
  • Treat "not subject to FDA regulation" as a red flag; it was the core misrepresentation in the Scalpa scheme between 2018 and 2020.
  • Report suspected unapproved injectables to the FDA's Office of Criminal Investigations, the agency that handled this case.

For clinics, distributors and med spas

  • Verify that every device and drug in inventory — pens, fillers, neuromodulators — has documented FDA approval.
  • Note that the Nov. 5, 2025 FDA warning put website operators on notice, and this plea shows the consequences for executives: a four-to-eight-year prison term, $800,000 in forfeiture and restitution for the entire conduct.

Risk & Opportunity Assessment

Commercial RiskMediumThe scheme ran for nearly three years (2018–2020) through direct marketing, and Cleveland agreed to forfeit $800,000 plus restitution for the full scope of conduct — a template for how enforcement can end a gray-market injectables business.
Competitive RiskMediumLegitimate FDA-approved injectable brands compete with cheaper unapproved products; this conviction and the Nov. 5, 2025 FDA warning reduce the gray market's ability to sell openly, benefiting compliant manufacturers.
Regulatory RiskHighThe FDA issued a specific warning on Nov. 5, 2025 about unapproved botulinum toxin products, and the DOJ Health and Safety Unit prosecuted this case — sellers of unapproved injectables now face criminal exposure, cross-border pursuit (the Colombia arrest) and prison terms.
Reputation RiskMediumAdverse events including botulism symptoms tied to unapproved products can erode consumer trust in the entire aesthetic injectables category, while Cleveland's personal reputation is critically damaged by the plea.
Technology DisruptionLowNo technology shift is at play; the case concerns regulatory compliance of existing injectable products and delivery devices.
Commercial OpportunityMediumCompliant manufacturers of FDA-approved neuromodulators and hyaluronic acid fillers stand to gain as enforcement removes unscrupulous competitors and signals a cleaner market.